Olaparib-related seronegative inflammatory arthritis: first report in the literature

Basit Öğe Kaydı
dc.authoridŞenol Kobak / 0000-0001-8270-640Xen_US
dc.authorscopusidŞenol Kobak / 12782228700
dc.authorwosidŞenol Kobak / AAO-2482-2020
dc.contributor.authorKobak, Şenol
dc.date.accessioned2020-08-30T20:06:11Z
dc.date.available2020-08-30T20:06:11Z
dc.date.issued2021
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractCancer is among the most common causes of death worldwide. Recently, revolutionary targeted smart drugs have been used in the treatment of various malignancies. One of these intelligent molecules is PARP inhibitors, which have the ability to interfere with DNA damage repair systems (1). PARPs are an enzyme family of 17 members, of which PARP1 is the best described protein. PARP1 plays a critical role in the base excision–repair pathway that controls the repair of single-strand breaks in DNA. Olaparib is the most studied PARP inhibitor, with activity against PARP1 and PARP2 (2). Many studies have demonstrated the efficacy and safety of olaparib in the treatment of ovarian, breast, and stomach cancers (3). No musculoskeletal system side effects associated with olaparib have been reported in the literature. Herein, we report the development of olaparib-related seronegative arthritis in a female patient with ovarian cancer.en_US
dc.identifier.citationKobak, S. (2020). Olaparib-related seronegative inflammatory arthritis: first report in the literature. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. https://doi.org/10.1080/03009742.2020.1732462en_US
dc.identifier.doi10.1080/03009742.2020.1732462en_US
dc.identifier.issn0300-9742en_US
dc.identifier.issn1502-7732en_US
dc.identifier.pmid32425082en_US
dc.identifier.scopus2-s2.0-85085277764en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1080/03009742.2020.1732462
dc.identifier.urihttps://hdl.handle.net/20.500.12713/407
dc.identifier.wosWOS:000537034000001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorKobak, Şenolen_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofScandinavian Journal of Rheumatologyen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleOlaparib-related seronegative inflammatory arthritis: first report in the literatureen_US
dc.typeLetteren_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Olaparib-related seronegative inflammatory arthritis_ fırst report in the literature.pdf
Boyut:
118.59 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu